{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002073","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.995441+00:00","generated_at":"2026-06-07T02:07:10.383227+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Protagonist updates pipeline: rusfertide Ph3 enrollment Q1 2024; JNJ-2113 Ph3 psoriasis data Nov 2024","bullets":["Rusfertide Phase 3 VERIFY study enrollment completion expected Q1 2024; primary endpoint similar to Phase 2.","Phase 2 REVIVE showed 69.2% responder rate vs 18.5% placebo (p=0.0003); durable Hct control to 2.5 years.","Rusfertide improved fatigue (p=0.0074) and concentration (p=0.0018) scores; ferritin normalized over 2.5 years.","JNJ-2113 Phase 3 ICONIC-LEAD psoriasis primary completion ~Nov 2024; Phase 2b ANTHEM UC completion ~Nov 2024.","Anticipated rusfertide NDA filing Q4 2026; JNJ-2113 NDA filing expected 2025/2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002073","json":"https://secwatch.observer/filing/0001104659-24-002073.json","markdown":"https://secwatch.observer/filing/0001104659-24-002073.md","text":"https://secwatch.observer/filing/0001104659-24-002073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924002073/0001104659-24-002073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924002073/tm242310d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:07:10.383227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}